CureVac Expected to Post Q1 2024 Earnings of ($0.14) Per Share (NASDAQ:CVAC)

CureVac (NASDAQ:CVAC) – Research analysts at Leerink Partnrs issued their Q1 2024 earnings per share estimates for shares of CureVac in a research report issued to clients and investors on Friday, April 26th. Leerink Partnrs analyst M. Foroohar expects that the company will post earnings per share of ($0.14) for the quarter. Leerink Partnrs has a “Market Perform” rating on the stock. The consensus estimate for CureVac’s current full-year earnings is ($0.97) per share. Leerink Partnrs also issued estimates for CureVac’s Q2 2024 earnings at ($0.14) EPS, Q3 2024 earnings at ($0.13) EPS, Q4 2024 earnings at ($0.13) EPS and FY2025 earnings at ($0.57) EPS.

A number of other equities analysts also recently commented on CVAC. SVB Leerink downgraded shares of CureVac from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $12.00 to $4.00 in a research report on Thursday, April 25th. Guggenheim reissued a “neutral” rating on shares of CureVac in a report on Friday, April 5th. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, CureVac currently has an average rating of “Hold” and a consensus price target of $8.33.

CureVac Price Performance

Shares of NASDAQ CVAC opened at $2.52 on Monday. The stock has a fifty day moving average price of $3.02 and a 200 day moving average price of $4.07. CureVac has a 1-year low of $2.21 and a 1-year high of $12.36. The company has a quick ratio of 2.43, a current ratio of 2.57 and a debt-to-equity ratio of 0.07.

Institutional Trading of CureVac

Hedge funds and other institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. increased its holdings in CureVac by 95.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,738 shares of the company’s stock valued at $39,000 after buying an additional 2,804 shares in the last quarter. Deutsche Bank AG grew its holdings in shares of CureVac by 5.1% in the 3rd quarter. Deutsche Bank AG now owns 72,510 shares of the company’s stock worth $495,000 after acquiring an additional 3,491 shares during the period. Swiss National Bank grew its holdings in shares of CureVac by 1.8% in the 3rd quarter. Swiss National Bank now owns 221,406 shares of the company’s stock worth $1,462,000 after acquiring an additional 3,925 shares during the period. Optiver Holding B.V. increased its stake in CureVac by 2,407.0% in the 3rd quarter. Optiver Holding B.V. now owns 6,844 shares of the company’s stock valued at $47,000 after purchasing an additional 6,571 shares in the last quarter. Finally, Federated Hermes Inc. raised its holdings in CureVac by 33.3% during the third quarter. Federated Hermes Inc. now owns 40,000 shares of the company’s stock worth $273,000 after purchasing an additional 10,000 shares during the last quarter. Institutional investors and hedge funds own 17.26% of the company’s stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.